| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | END; HHT1; ORW1 |
| WB Predicted band size | 71 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ENG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ENG抗体的3篇参考文献，涵盖其在不同疾病中的研究应用：
---
1. **文献名称**: *"Endoglin调控机制及其在遗传性出血性毛细血管扩张症(HHT)中的作用*
**作者**: Fernández-L A, et al.
**摘要**: 该研究通过分析ENG基因的mRNA稳定性调控机制，揭示了HHT患者中Endoglin蛋白表达异常的原因。实验证明，特定miRNA(如miR-26a)通过结合ENG mRNA的3'UTR区域影响其翻译，为ENG抗体在HHT诊断及靶向治疗中的应用提供了理论基础。
---
2. **文献名称**: *"抗Endoglin抗体抑制肿瘤血管生成及转移的临床前研究*
**作者**: Rosen LS, et al.
**摘要**: 研究利用人源化抗Endoglin单克隆抗体(如TRC105)，在结肠癌和乳腺癌小鼠模型中验证其抗血管生成作用。结果显示，抗体通过阻断TGF-β信号通路显著抑制肿瘤血管新生，并增强化疗药物递送效率，提示ENG抗体在癌症联合治疗中的潜力。
---
3. **文献名称**: *"可溶性Endoglin(sEng)与子痫前期的病理机制及抗体干预*
**作者**: Venkatesha S, et al.
**摘要**: 该研究发现子痫前期患者胎盘中sEng水平异常升高，与血管功能障碍相关。通过大鼠模型注射抗ENG抗体，可有效缓解高血压和蛋白尿症状，证实sEng是子痫前期的关键致病因子，为抗体靶向治疗提供了实验依据。
---
以上文献分别从遗传病、肿瘤及妊娠并发症的角度，阐述了ENG抗体的基础研究与临床应用价值。
ENG antibodies target endoglin (CD105), a transmembrane glycoprotein predominantly expressed on vascular endothelial cells. As a coreceptor in the TGF-β signaling pathway, endoglin regulates angiogenesis, vascular remodeling, and endothelial cell proliferation. Its overexpression is linked to pathological angiogenesis in cancers and vascular diseases.
First characterized in the 1990s, ENG antibodies emerged as critical tools for studying endothelial biology. They help distinguish activated endothelial cells (high endoglin) from quiescent ones in tumors or inflamed tissues. Clinically, ENG serves as a biomarker for hereditary hemorrhagic telangiectasia (HHT), where genetic mutations cause vascular malformations. Anti-ENG immunohistochemistry aids in diagnosing HHT-related vascular lesions and assessing tumor microvessel density as a prognostic indicator in cancers.
Therapeutically, ENG-targeting antibodies like carotuximab (TRC105) have been developed to inhibit angiogenesis in solid tumors by blocking TGF-β/endoglin pathways. Recent research also explores ENG antibody-conjugated nanoparticles for targeted drug delivery. Challenges remain in optimizing specificity and minimizing off-target effects, but ENG antibodies continue to bridge translational research and clinical applications in vascular disorders and oncology.
×
